Literature DB >> 18949577

Elevated cholesterol precursors other than cholestanol can also be a hallmark for CTX.

M G M de Sain-van der Velden1, A Verrips, B H C M T Prinsen, M de Barse, R Berger, G Visser.   

Abstract

Cerebrotendinous xanthomatosis (CTX) is an inborn error of bile acid synthesis in which hepatic conversion of cholesterol to cholic and chenodeoxycholic acids is impaired. Patients have abnormal bile alcohols in urine, normal to increased plasma cholesterol concentrations and increased concentrations of plasma cholestanol. Little is known about cholesterol precursors in CTX, however. We studied cholesterol and phytosterol profiles in two siblings with CTX during follow-up. While cholesterol concentrations were low in both patients, plasma cholestanol was 6-fold higher compared to control values. In addition, both siblings had a more than 100-fold increase in 7-dehydrocholesterol (7DHC) and 8-dehydrocholesterol (8DHC). Lathosterol, lanosterol and sitosterol were increased in both patients while concentrations of desmosterol and campesterol were normal. In addition, plasma lathosterol/cholesterol ratios were significantly elevated. After treatment with chenodeoxycholate, both patients showed a marked decrease in cholestanol, 7DHC, 8DHC, lathosterol, lanosterol and sitosterol. In addition, the lathosterol/cholesterol ratio normalized, indicating that overall cholesterol synthesis was sufficiently suppressed. This study shows that elevated cholesterol precursors, other than cholestanol, can be a hallmark for CTX.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18949577     DOI: 10.1007/s10545-008-0963-1

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  24 in total

1.  Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects.

Authors:  G F Watts; R P Naoumova; J M Kelly; F M Riches; K D Croft; G R Thompson
Journal:  Am J Physiol       Date:  1997-09

2.  Bile alcohol metabolism in man. Conversion of 5beta-cholestane-3alpha, 7alpha,12alpha, 25-tetrol to cholic acid.

Authors:  G Salen; S Shefer; T Setoguchi; E H Mosbach
Journal:  J Clin Invest       Date:  1975-07       Impact factor: 14.808

3.  Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system.

Authors:  J H Menkes; J R Schimschock; P D Swanson
Journal:  Arch Neurol       Date:  1968-07

4.  High levels of plant sterols and cholesterol precursors in cerebrotendinous xanthomatosis.

Authors:  M Kuriyama; J Fujiyama; T Kasama; M Osame
Journal:  J Lipid Res       Date:  1991-02       Impact factor: 5.922

5.  Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis.

Authors:  J J Cali; C L Hsieh; U Francke; D W Russell
Journal:  J Biol Chem       Date:  1991-04-25       Impact factor: 5.157

6.  Fine-mapping, mutation analyses, and structural mapping of cerebrotendinous xanthomatosis in U.S. pedigrees.

Authors:  M H Lee; S Hazard; J D Carpten; S Yi; J Cohen; G T Gerhardt; G Salen; S B Patel
Journal:  J Lipid Res       Date:  2001-02       Impact factor: 5.922

7.  Sterol parameters as markers of liver function in primary biliary cirrhosis before and after liver transplantation.

Authors:  Katriina Nikkilä; Tatu A Miettinen; Krister V A Höckerstedt; Helena Isoniemi
Journal:  Transpl Int       Date:  2005-02       Impact factor: 3.782

8.  Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use.

Authors:  M Kuriyama; Y Tokimura; J Fujiyama; Y Utatsu; M Osame
Journal:  J Neurol Sci       Date:  1994-08       Impact factor: 3.181

9.  Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.

Authors:  T Nakamura; Y Matsuzawa; K Takemura; M Kubo; H Miki; S Tarui
Journal:  Metabolism       Date:  1991-07       Impact factor: 8.694

10.  Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid.

Authors:  V M Berginer; G Salen; S Shefer
Journal:  N Engl J Med       Date:  1984-12-27       Impact factor: 91.245

View more
  16 in total

1.  Conversion of 7-dehydrocholesterol to 7-ketocholesterol is catalyzed by human cytochrome P450 7A1 and occurs by direct oxidation without an epoxide intermediate.

Authors:  Raku Shinkyo; Libin Xu; Keri A Tallman; Qian Cheng; Ned A Porter; F Peter Guengerich
Journal:  J Biol Chem       Date:  2011-08-03       Impact factor: 5.157

2.  Evaluation of cholesterol metabolism in cerebrotendinous xanthomatosis.

Authors:  Andrea Mignarri; Alessandro Magni; Marina Del Puppo; Gian Nicola Gallus; Ingemar Björkhem; Antonio Federico; Maria Teresa Dotti
Journal:  J Inherit Metab Dis       Date:  2015-07-08       Impact factor: 4.982

3.  A useful multi-analyte blood test for cerebrotendinous xanthomatosis.

Authors:  Andrea E DeBarber; Jenny Luo; Roberto Giugliani; Carolina F M Souza; John Pei-Wen Chiang; Louise S Merkens; Anuradha S Pappu; Robert D Steiner
Journal:  Clin Biochem       Date:  2014-04-21       Impact factor: 3.281

4.  Profiling and Imaging Ion Mobility-Mass Spectrometry Analysis of Cholesterol and 7-Dehydrocholesterol in Cells Via Sputtered Silver MALDI.

Authors:  Libin Xu; Michal Kliman; Jay G Forsythe; Zeljka Korade; Anthony B Hmelo; Ned A Porter; John A McLean
Journal:  J Am Soc Mass Spectrom       Date:  2015-03-31       Impact factor: 3.109

5.  Probing lipid-protein adduction with alkynyl surrogates: application to Smith-Lemli-Opitz syndrome.

Authors:  Katherine Windsor; Thiago C Genaro-Mattos; Hye-Young H Kim; Wei Liu; Keri A Tallman; Sayuri Miyamoto; Zeljka Korade; Ned A Porter
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

6.  Oxysterols from free radical chain oxidation of 7-dehydrocholesterol: product and mechanistic studies.

Authors:  Libin Xu; Zeljka Korade; Ned A Porter
Journal:  J Am Chem Soc       Date:  2010-02-24       Impact factor: 15.419

7.  On the formation of 7-ketocholesterol from 7-dehydrocholesterol in patients with CTX and SLO.

Authors:  Ingemar Björkhem; Ulf Diczfalusy; Anita Lövgren-Sandblom; Lena Starck; Monica Jonsson; Keri Tallman; Henrik Schirmer; Lilian Bomme Ousager; Peter J Crick; Yuqin Wang; William J Griffiths; F Peter Guengerich
Journal:  J Lipid Res       Date:  2014-04-25       Impact factor: 5.922

8.  Oxidation of 7-dehydrocholesterol and desmosterol by human cytochrome P450 46A1.

Authors:  Sandeep Goyal; Yi Xiao; Ned A Porter; Libin Xu; F Peter Guengerich
Journal:  J Lipid Res       Date:  2014-07-13       Impact factor: 5.922

9.  Autism spectrum disorder: an early and frequent feature in cerebrotendinous xanthomatosis.

Authors:  Bianca M L Stelten; Olivier Bonnot; Hidde H Huidekoper; Francjan J van Spronsen; Peter M van Hasselt; Leo A J Kluijtmans; Ron A Wevers; Aad Verrips
Journal:  J Inherit Metab Dis       Date:  2017-09-11       Impact factor: 4.982

10.  Cerebrotendinous xanthomatosis, a metabolic disease with different neurological signs: two case reports.

Authors:  Maria Donata Di Taranto; Monica Gelzo; Carola Giacobbe; Marco Gentile; Gennaro Marotta; Silvia Savastano; Antonio Dello Russo; Giuliana Fortunato; Gaetano Corso
Journal:  Metab Brain Dis       Date:  2016-05-26       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.